New immunotherapy combo aims to shrink lung tumors before surgery
NCT ID NCT07241819
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests the immunotherapy drug ivonescimab, alone or with chemotherapy, before and after surgery for people with stage II-IIIB non-small cell lung cancer that can be removed. The goal is to see if tailoring treatment based on PD-L1 levels can reduce toxicity while keeping the cancer from coming back. About 66 participants will be split into groups based on their PD-L1 levels and receive different combinations of ivonescimab and chemo before surgery, followed by ivonescimab alone after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ivonescimab (an immunotherapy drug) alone or with platinum-based chemotherapy
What this could lead to
If successful, this could offer a more personalized, less toxic treatment approach for resectable lung cancer, potentially improving outcomes while reducing side effects.
What could go wrong
This is an early Phase 2 trial with only 66 participants, so results may not apply broadly. The drug may not improve outcomes or could cause serious immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for II-IIIB (T3N2) RESECTABLE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••